Medical

Magazine articles on health care providers, pharmaceutical companies, and medical technology.

Old Articles: <Older 2981-2990 Newer>

The Motley Fool June 27, 2006 Stephen D. Simpson	Barr Bulks Up For Barr Labs, buying Pliva adds manufacturing capabilities, market opportunities, and pipeline candidates. Investors, take note.
The Motley Fool June 27, 2006 Brian Lawler	Cephalon Stays Busy The announcement of Gabitril's phase 3 failure was definitely not good news for Cephalon. However, if the market panics and drives the stock down, investors could find themselves with a great buying opportunity.
BusinessWeek July 3, 2006 Arlene Weintraub	When Dad Bets On An Archrival LCA-Vision Inc. regroups after its CEO disclosed a hefty investment in another vision center
Scientific American July 2006 JR Minkel	Dangling a Carrot for Vaccines Drug companies do not see much of a market in treating diseases of developing nations. Michael Kremer hopes to change that with a plan that taps the profit motive.
The Motley Fool June 26, 2006 Stephen D. Simpson	Is Novartis the Future of Generics? Merck's recent pricing action might just be the beginning of the end of generics as we know them. Investors, take note.
The Motley Fool June 26, 2006 Stephen D. Simpson	J&J Makes an Expensive Deal J&J announced that it has reached an agreement with Pfizer to acquire the latter's consumer health-care business for $16.6 billion in cash. Consumer health is a fine business line, but is it worth this much money? Investors, take note.
BusinessWeek July 3, 2006 Catherine Arnst	A Ton Of Prevention The pros and cons of two drugs that may halve your risk of breast cancer.
The Motley Fool June 23, 2006 Stephen D. Simpson	Neurocrine Biosciences: From Bad to Worse Pfizer's departure is a serious, though not fatal, blow to the biotech. While this story may yet have a happy ending, there's going to be a lot of nervous waiting between now and then. Investors, take note.
The Motley Fool June 22, 2006 Stephen D. Simpson	Merck Goes on the Attack Predator becomes prey in this latest twist in the generics game. Given how much the markets hate uncertainty, that could mean that big generic drug companies might go on sale for patient long-term investors.
Job Journal June 18, 2006 Julia Hollister	Nursing Assistants Job prospects in the U.S. for nursing assistants are expected to be excellent due to increasing demand for long-term care from a retired population -- which is expected to double in the next 20 years.
<Older 2981-2990 Newer> Return to current articles.